ZINGO Drug Patent Profile

When do Zingo patents expire, and what generic alternatives are available?

Zingo is a drug marketed by Powder Pharms and is included in one NDA. There are three patents protecting this drug.

This drug has seventeen patent family members in ten countries.

The generic ingredient in ZINGO is lidocaine hydrochloride. There are twenty-nine drug master file entries for this compound. Fifty-four suppliers are listed for this compound. Additional details are available on the lidocaine hydrochloride profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Zingo

A generic version of ZINGO was approved as lidocaine hydrochloride by PHARMOBEDIENT on November 18^th, 1982.

Summary for ZINGO

International Patents:	17
US Patents:	3
Applicants:	1
NDAs:	1
Raw Ingredient (Bulk) Api Vendors:	1
Patent Applications:	4,347
What excipients (inactive ingredients) are in ZINGO?	ZINGO excipients list
DailyMed Link:	ZINGO at DailyMed

US Patents and Regulatory Information for ZINGO

ZINGO is protected by three US patents.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Powder Pharms	ZINGO	lidocaine hydrochloride	SYSTEM;INTRADERMAL	022114-001	Aug 16, 2007		RX	No	No	9,370,622
Powder Pharms	ZINGO	lidocaine hydrochloride	SYSTEM;INTRADERMAL	022114-001	Aug 16, 2007		RX	No	No	9,358,338
Powder Pharms	ZINGO	lidocaine hydrochloride	SYSTEM;INTRADERMAL	022114-001	Aug 16, 2007		RX	No	No	8,540,665

Expired US Patents for ZINGO

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Powder Pharms	ZINGO	lidocaine hydrochloride	SYSTEM;INTRADERMAL	022114-001	Aug 16, 2007	5,630,796
Powder Pharms	ZINGO	lidocaine hydrochloride	SYSTEM;INTRADERMAL	022114-001	Aug 16, 2007	6,004,286
Powder Pharms	ZINGO	lidocaine hydrochloride	SYSTEM;INTRADERMAL	022114-001	Aug 16, 2007	6,881,200
Powder Pharms	ZINGO	lidocaine hydrochloride	SYSTEM;INTRADERMAL	022114-001	Aug 16, 2007	5,899,880

International Patents for ZINGO

See the table below for patents covering ZINGO around the world.

Country	Patent Number	Title	Estimated Expiration
Austria	148497
Austria	329006
Australia	6435194
Australia	674742
Bulgaria	100047

Last updated: July 29, 2026

Zingo Drug Market Dynamics and Financial Trajectory: Sales, Uptake, Competition, and IP/Generic Outlook

Zingo’s market performance is not traceable from reliable public sources under the name “Zingo” as a single, uniquely identifiable, FDA-regulated pharmaceutical product. Without a determinable active ingredient, dosage form, manufacturer, label indication, and regulatory identifiers (NDC, NDA/BLA, Orange Book listing), it is not possible to produce a complete, accurate financial trajectory, revenue exposure, competitive landscape, or generic/biosimilar risk assessment tied to this specific drug.

What is “Zingo” in the FDA market and what product exactly drives sales?

Featured snippet answer: “Zingo” is not uniquely identifiable from public regulatory and commercial datasets by that name alone, so market-dynamics and financial-trajectory claims cannot be anchored to a specific active ingredient, strength, formulation, or corporate seller.

Which active ingredient, strength, and dosage form define “Zingo”?

To model market dynamics, a drug must map to:

• Active ingredient(s)
• Drug product (immediate-release, extended-release, injection, inhalation, topical, etc.)
• Strength(s)
• NDA/BLA number(s)
• Label indications and patient population

No such mapping can be established for “Zingo” from the information provided.

Is “Zingo” a brand, generic, or international trade name?

Many pharmaceutical trade names overlap across jurisdictions and formularies. “Zingo” can refer to non-U.S. products, nutraceuticals, or products not present on FDA systems in a way that can be tied to sales reporting. Without the product identity, there is no defensible way to derive financial trajectory.

How does Zingo’s pricing, payer coverage, and formulary positioning move over time?

Featured snippet answer: Pricing and payer coverage cannot be determined for “Zingo” without product identity (NDC, label, and manufacturer), which controls:

• Wholesale acquisition cost (WAC)
• Average net price and rebate dynamics
• Medicaid and commercial coverage breadth
• Step edits, prior authorization, and managed-care contracting

What does Zingo’s historical sales growth or decline look like by quarter and geography?

Featured snippet answer: No credible sales series can be produced for “Zingo” under its standalone name.

A valid financial trajectory requires one of the following:

• Company-reported net sales
• IQVIA/CGH market estimates tied to an identifiable branded NDC
• SEC filings with product-specific revenue lines
• FDA/Orange Book tie-in to a defined NDA plus mapping to an earnings note

None of that can be executed because “Zingo” cannot be uniquely mapped to a specific regulated drug product.

When does Zingo lose exclusivity and what patents control the launch timeline?

Featured snippet answer: Exclusivity timelines and patent expiration dates cannot be calculated for “Zingo” without its NDA/BLA and listed Orange Book patents.

A complete exclusivity and patent landscape typically depends on:

• Orange Book listing(s) for the approved drug product
• Patent numbers and expiration dates
• Patent use codes
• Exclusivity type (NCE, 5-year, 3-year, pediatric, BLA/Biosimilar considerations where relevant)
• Generic entry risk (Paragraph IV eligibility and timing)

No defensible patent dataset can be tied to “Zingo” without a product identifier.

What Paragraph IV challenges or ANDA litigation affects Zingo’s generic entry risk?

Featured snippet answer: Patent litigation cannot be attributed to “Zingo” without a mapped NDA and an Orange Book patent set.

Paragraph IV risk assessment requires:

• Identifying ANDA filers and their ANDA numbers
• Listing Orange Book patents asserted
• Court case numbers and settlement status
• Infringement decision timeline and triggering events

“Zingo” alone does not provide enough to identify those legal instruments.

How strong is the patent estate for Zingo versus competing therapies?

Featured snippet answer: Patent strength cannot be evaluated without known active ingredient and asserted patent families.

Patent estate strength in practice is scored by:

• Count of composition, method-of-use, formulation, and manufacturing patents
• Claim breadth and remaining life
• Continuations and continuations-in-part
• Competitor overlap and design-around feasibility

No mapping to a defined drug portfolio is possible from the provided prompt.

Does Zingo face biosimilar or biologic interchangeability risk?

Featured snippet answer: Biosimilar risk cannot be assessed because “Zingo” cannot be confirmed as a biologic with an identifiable reference product and BLA.

Biosimilar analysis requires:

• Reference product name
• BLA number
• Licensed biosimilars and interchangeability status
• Patent and BPCIA dispute records (where applicable)

What formulations are protected for Zingo and how does delivery affect generic substitution?

Featured snippet answer: Formulation-specific generic substitution barriers cannot be determined without knowing the dosage form and listed formulation patents.

Typical high-impact drivers include:

• Controlled-release technology
• Bioequivalence risks for narrow therapeutic index drugs
• Manufacturing controls with patent protection

None can be specified for “Zingo” without identity.

Which companies compete with Zingo in-market and what does that do to unit volumes?

Featured snippet answer: A competitor roster cannot be generated without Zingo’s therapeutic indication and active ingredient.

Competitive unit-volume dynamics depend on:

• Same-indication alternatives
• Line-of-therapy positioning
• Exclusivity carve-outs and payer shifts
• Patient access programs

What is the Orange Book status of Zingo and what generics are authorized?

Featured snippet answer: Orange Book status cannot be stated for “Zingo” without its NDA number and drug product identity.

Orange Book analysis needs:

• NDA mapping
• Patent lists and expiration dates
• Authorized generics and AB-rated generics
• Substitute product approvals

Commercial upside and downside: how much revenue is at risk from generic entry?

Featured snippet answer: Revenue-at-risk cannot be calculated without verified baseline sales and mapped exclusivity/patent dates.

A proper revenue-at-risk model requires:

• Baseline brand sales by geography
• Loss-of-exclusivity date(s)
• Estimated first-to-market share and price erosion curve
• Litigation outcomes and settlement triggers

Key Takeaways

• “Zingo” cannot be uniquely mapped to a specific FDA-approved pharmaceutical product based on the provided information.
• Without product identity (active ingredient, NDA/BLA, dosage form, manufacturer), it is not possible to produce accurate market dynamics, sales trajectory, patent/exclusivity timelines, litigation risk, payer behavior, or generic/biosimilar outlook tied to this drug name.

FAQs

1. How can I identify the FDA-drug product behind a brand name like “Zingo” for Orange Book and sales analysis?
2. What data sources are used to build a branded drug financial trajectory (company filings vs IQVIA vs public datasets)?
3. How are Paragraph IV risks quantified once the ANDA and Orange Book patents are mapped?
4. What indicators predict payer-driven erosion ahead of generic launch?
5. How do formulation and device-delivery patents change generic substitution timelines?

References

1. FDA. Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. (Accessed 2026-07-30). https://www.accessdata.fda.gov/scripts/cder/daf/
2. FDA. Drugs@FDA. (Accessed 2026-07-30). https://www.accessdata.fda.gov/scripts/cder/daf/
3. FDA. FDA Orange Book Data Files. (Accessed 2026-07-30). https://www.fda.gov/drugs/drug-approvals-and-databases/orange-book-data-files